The fight against cancer has never looked brighter. This is the 21st century, and the 21st century is known for its technological advancements. Cancer research has definitely benefited from these advancements, and it’s setting the precedent in saving lives. Dr. Clay Siegall is the CEO for one of the industry’s most beloved organizations. He has helped to guide Seattle Genetics straight to the top of the ranks. This company produces some of the best cancer-fighting medications of all-time. Since its inception in 1998, this tiny startup company has grown into a powerhouse of cancer research success.
Siegall has always had a strong interest in the medical field, and he has used his strong interest to better mankind. As a very young man, Siegall’s father struggled with cancer and all of the complications that came with illness. Radical surgeries and amputations were the norm back in those days, but there had to be a more proficient way of treating the disease. This is what set this extraordinary man in motion, and this is what set the ball in motion. Treating this illness without the harsh complications was a challenge and Seattle Genetics was no exception in the beginning. The company was simply spending more than it was making. After bringing in a top-notch sales team that had expertise in business and biotechnology, the company began to secure many lucrative deals. Seattle Genetics began to make a name for itself, and its top medication has set the precedent in cancer therapies.
After securing its IPO, the sky was the limit. Seattle Genetics does a great job of pulling in revenue from production partnerships, from the selling of its own medications and from the licensing of its own technologies. On top of that, Siegall has helped to raise over a billion dollars via private and public fundraising. What more can you ask for? Dr. Clay Siegall has set the bar very high and Seattle Genetics has set newer and better trends throughout the industry.